The subject of the invention is the BK124.1 compound of Formula I, for use in the treatment of cancer, wherein the cancer is leukemia or another cancer characterized by a clonal increase in the number of white blood cells, wherein the cancer shows resistance to previous treatments, in particular multidrug resistance.

The Nencki Institute is a co-applicant of the patent with Centre of Molecular and Macromolecular Studies PAS and Medical Univeristy of Warsaw

For more information contact Technology Transfer Office.